MARKET WIREYahoo! Finance Canada • 16h ago
Immunome, Inc. (IMNM) Stock Price, News, Quote & HistoryYahoo! Finance Canada report covering Immunome Inc. (IMNM) market action, institutional positioning, and fundamental catalysts.
Why IMNM Stock slipped -0.44% Today — RQD Quant Desk Flash
$18.21 -0.44% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $18.16
Immunome Inc. (IMNM) carries a Roarable Rating of E (Strong Sell) with 26/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $2.15B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on IMNM Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is IMNM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Immunome Inc. (NASDAQ: IMNM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $18.21 (-0.44% 1D, market cap $2.15B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 3/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, IMNM ranks #902 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does IMNM compare to LKFT and PRGO in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IMNM carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LKFT (Lakefront Biotherapeutics) holds a D+ grade (57/100 RQD, P/E N/A, ROIC —, cap $2.13B) and PRGO (Perrigo Company plc) posts a D grade (49/100 RQD, P/E N/A, ROIC -13.6%, cap $2.19B). Among the 5-stock peer group, AUPH leads on earnings multiple (8.0x) while AUPH leads on capital efficiency (16.5% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for IMNM?
▼
Per IMNM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001472012), Immunome Inc. generated $6.9M in revenue (-23.2% YoY), -$212.4M in net income, and -$200.6M in free cash flow against $683.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $18.16 (-0.27%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (26/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-14.4% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IMNM)Realized 20D OHLCV Swing Band: ±10.3%
Deterministic 5-Pillar Attribution (26/100 Composite)
🔍 WHY IMNM SCORES 26/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (42% of score)
Altman Z-Score 25.03 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
▲ #2 Bullish Driver: Cash Engine Quality+5/20 pts (19% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$17.58+1.9% Next Q
18
Q2 (-2Q)Grade E$17.92+4.7% Next Q
21
Q3 (-1Q)Grade E$18.77-3% Next Q
23
CurrentGrade E$18.21-10.5% Hist 90D α
26
Trajectory: E (18) → E (26)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a IMNM Turnaround Squeeze
While IMNM currently carries a cautious 26/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($22.04) and Max Pain ($19.12) forces dealer call-delta covering toward $31.56.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $IMNM• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “IMNM Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why IMNM Stock slipped -0.44% Today — RQD Quant Desk Flash
Immunome Inc. (IMNM) slipped -0.44% to $18.21, trading at 23% of its 52-week range ($14.64 – $30.06). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 23% of its 52-week range ($14.64 – $30.06) with RSI-14 at 39.7 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±10.3% around $18.21 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live IMNM Headlines & Catalysts
MARKET WIREYahoo Finance • 19h ago
Immunome (IMNM) Following FDA Clearance Is Its Oncology Story Back In Value FocusYahoo Finance report covering Immunome Inc. (IMNM) market action, institutional positioning, and fundamental catalysts.
MARKET WIREInvesting.com • 22h ago
Immunome stock price target maintained at $40 by H.C. WainwrightInvesting.com report covering Immunome Inc. (IMNM) market action, institutional positioning, and fundamental catalysts.
RISK WATCHSimply Wall Street • 1d ago
Immunome (IMNM) Stock Dropped, What Is Behind The Latest Attention?Simply Wall Street report covering Immunome Inc. (IMNM) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
Immunome's Nov. 10 conference presentation will stream liveStock Titan report covering Immunome Inc. (IMNM) market action, institutional positioning, and fundamental catalysts.
MARKET WIREGuruFocus • 1d ago
IMNM Reiterated by Wedbush -- Price Target Maintained at $35GuruFocus report covering Immunome Inc. (IMNM) market action, institutional positioning, and fundamental catalysts.
MARKET WIREGuruFocus • 1d ago
Immunome's Varegacestat MAA Validated by EMA, Shares Trade at ElGuruFocus report covering Immunome Inc. (IMNM) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Traders Daily • 1d ago
Understanding Momentum Shifts in (IMNM)Stock Traders Daily report covering Immunome Inc. (IMNM) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 3d ago
Immunome Announces EMA Validation of Marketing Authorization Application for Varegacestat for the Treatment of Adults with Desmoid TumorsBOTHELL, Wash., October 30, 2026--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the Eur
RISK WATCHBenzinga • 4d ago
Immunome Says EMA Validates MAA For Varegacestat, Investigational, Oral, Once-Daily Gamma Secretase Inhibitor, For Treatment Of Adults With Desmoid TumorsThe Marketing Authorization Application (MAA) is supported by positive Phase 3 RINGSIDE results demonstrating statistically significant improvements across the primary and all key secondary endpointsIf approved,
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IMNM)
- ✓Walkthrough of IMNM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
IMNM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -21.95%📐 HORIZONTAL RANGE
2026-11-03O $18.29H $18.29L $18.21C $18.21VOL 1.27M
RES: $26.44SUP: $15.44SMA50: $22.04SMA200: $22.45
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
IMNM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. -23.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on IMNM today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for IMNM. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for IMNM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IMNM)
Health Care Rank #902 of 1016
⚔️ LKFT vs IMNM Full Matrix →
1. Head-to-Head Health Care Peer Comparison (IMNM vs. LKFT, PRGO, PVLA, AUPH)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Immunome Inc. (IMNM) ranks #902 by composite RQD confidence (26/100, grade E) and #244 by equity capitalization ($2.15B). Within this direct 5-issuer industry benchmark cohort, AUPH leads on earnings valuation at 8.0x trailing P/E, while AUPH leads on capital efficiency and profitability with 16.5% ROIC and 88.5% gross margin. AUPH currently holds the highest overall quantitative score in the immediate peer group at 74/100 (B) compared with IMNM at 26/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| IMNM
ACTIVE
Immunome Inc. | E | 26/100 | — | — | -35.0% | -0.44% | $2.15B | Benchmark Subject |
| LKFT Lakefront Biotherapeutics | D+ | 57/100 | — | — | — | -0.15% | $2.13B | /lkft-vs-imnm → |
| PRGO Perrigo Company plc | D | 49/100 | — | 35.1% | -13.6% | -0.75% | $2.19B | /prgo-vs-imnm → |
| PVLA Palvella Therapeutics Inc. | D | 45/100 | — | — | -27.9% | -3.58% | $2.11B | /pvla-vs-imnm → |
| AUPH Aurinia Pharmaceuticals Inc | B | 74/100 | 8.0x | 88.5% | 16.5% | -3.25% | $2.22B | /auph-vs-imnm → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001472012In its most recent audited fiscal period (FY2025, filed 2025-12-31), Immunome Inc. (IMNM) reported GAAP revenue of $6.9M (-23.2% vs. FY2024 revenue of $9.0M , and -50.5% cumulative change since FY2023) , GAAP net income of -$212.4M, operating cash flow of -$190.9M, and free cash flow of -$200.6M (-70.1% YoY). On the balance sheet, IMNM closed FY2025 with $683.2M in total assets against $0 in total debt (Altman Z-Score: 25.03, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $6.9M | -$212.4M | -$190.9M | -$200.6M | $683.2M | — |
| FY2024 (FY) | 2024-12-31 | $9.0M | -$293.0M | -$110.8M | -$118.0M | $240.2M | — |
| FY2023 (FY) | 2023-12-31 | $14.0M | -$106.8M | -$7.6M | -$7.6M | — | — |
3. IMNM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs IMNM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Immunome Inc. (NASDAQ: IMNM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $18.21 (-0.44% 1D, market cap $2.15B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 3/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, IMNM ranks #902 in composite RQD confidence.
How does IMNM compare to LKFT and PRGO in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IMNM carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LKFT (Lakefront Biotherapeutics) holds a D+ grade (57/100 RQD, P/E N/A, ROIC —, cap $2.13B) and PRGO (Perrigo Company plc) posts a D grade (49/100 RQD, P/E N/A, ROIC -13.6%, cap $2.19B). Among the 5-stock peer group, AUPH leads on earnings multiple (8.0x) while AUPH leads on capital efficiency (16.5% ROIC).
What are the biggest fundamental strengths and SEC risk factors for IMNM?
Per IMNM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001472012), Immunome Inc. generated $6.9M in revenue (-23.2% YoY), -$212.4M in net income, and -$200.6M in free cash flow against $683.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is IMNM trading relative to its 50-day, 200-day, and 52-week technical levels?
IMNM last traded at $18.21 (-0.44% on volume of 1,271,234 shares), positioning the stock -17.38% below its 50-day simple moving average ($22.04) and -18.89% below its 200-day simple moving average ($22.45). Across its 52-week range of $14.64 to $30.06, IMNM sits at the 23.2% percentile with a 14-day RSI of 39.7 (NEUTRAL RANGE) and an implied next-earnings move of ±10.3% ($16.33 to $20.09).
IMNM Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is IMNM stock moving today?
Why IMNM Stock slipped -0.44% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 26/100 (E)
✓ STAGE-C NUMBER FIREWALL VERIFIED
IMNM — Immunome Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:26:33Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, IMNM scores 26 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:
- Fundamental Cash Engine: 5 / 20. Per the Roarable RQD rating, ROIC is -35% and FCF yield is -9.29%. For a prospective investor, this indicates the business is not currently generating cash returns on invested capital, and the valuation is not supported by present cash earnings.
- Whale 13F Flow: 4 / 20. Per the Roarable RQD rating, this pillar reflects institutional accumulation and options positioning. The low score suggests limited evidence of strong institutional conviction in the source data.
- Insider Conviction: 3 / 20. Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. The low score indicates weak insider-signal support.
- Macro Regime Fit: 3 / 20. Per the Roarable RQD rating, beta is 1.0 with sector sensitivity noted. The score implies the stock's regime fit is weak in the rating's framework.
- Forensic Balance Sheet: 11 / 20. Per the Roarable RQD rating, Altman Z is 25.03, Piotroski F is 3/9, and Debt/Equity is 0.5. This is the strongest pillar, though it remains below midpoint.
Taken together, the pillars point to a stock where cash generation and signal support are weak, while the balance sheet is comparatively the least concerning area. Upside drivers would need to come from a change in cash-generation trajectory, which the source data does not show. Valuation tradeoffs are difficult to assess because P/E and EV/EBITDA are not available in source data. This is an educational reading of the rating, not personalized financial advice.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $6.9M | $-224.1M | $-212.4M | N/A | $-200.6M | $653.5M | N/A |
| FY 2024 | $9.0M | $-305.8M | $-293.0M | N/A | $-118.0M | $143.4M | N/A |
| FY 2023 | $14.0M | $-109.5M | $-106.8M | N/A | $-7.6M | N/A | N/A |
Per the SEC financials, revenue declined from $14.0M in FY 2023 to $6.9M in FY 2025, while net losses were reported in every period shown. Per the market data, operating margin and net margin are both -60%, gross margin is 0%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 25.03 and the Piotroski F-Score is 3/9. Per the Roarable RQD rating, Debt/Equity is 0.5, and reported cash rose to $653.5M in FY 2025.
Recent Catalysts & News Wire Analysis
Per the recent news data, the feed contains six items, all tagged to IMNM. The headlines reference: market price and institutional coverage on Yahoo! Finance Canada; an article discussing the company's oncology story following FDA clearance (Yahoo Finance); a price target maintained at $40 by H.C. Wainwright (Investing.com); a Simply Wall Street article on a recent stock drop, flagged as RISK WATCH; a Stock Titan notice that a November 10 conference presentation will stream live; and a GuruFocus item reporting a Wedbush reiteration with price target maintained at $35. The only item carrying a RISK WATCH flag is the Simply Wall Street stock-drop piece. Per the Butterfly Supply-Chain Graph, supply chain is NONE, with no butterfly links and no proprietary signals.
Open Questions
- What is the company's revenue composition and source of the FY 2025 revenue of $6.9M?
- What drove the FY 2025 cash balance increase to $653.5M, and what is the debt position given that debt is reported as N/A?
- What are the P/E, EV/EBITDA, and EPS figures, which are absent from the source data?
- What is the trajectory of cash burn relative to the FCF of $-200.6M in FY 2025?
- What specific events are underlying the stock-drop and FDA-clearance coverage in the news feed?
IMNM Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Immunome Inc. (IMNM) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo! Finance Canada • 16h ago
Immunome, Inc. (IMNM) Stock Price, News, Quote & History Yahoo! Finance Canada report covering Immunome Inc. (IMNM) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 19h ago
Immunome (IMNM) Following FDA Clearance Is Its Oncology Story Back In Value Focus Yahoo Finance report covering Immunome Inc. (IMNM) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com • 22h ago
Immunome stock price target maintained at $40 by H.C. Wainwright Investing.com report covering Immunome Inc. (IMNM) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Simply Wall Street • 1d ago
Immunome (IMNM) Stock Dropped, What Is Behind The Latest Attention? Simply Wall Street report covering Immunome Inc. (IMNM) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
Immunome's Nov. 10 conference presentation will stream live Stock Titan report covering Immunome Inc. (IMNM) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE GuruFocus • 1d ago
IMNM Reiterated by Wedbush -- Price Target Maintained at $35 GuruFocus report covering Immunome Inc. (IMNM) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE GuruFocus • 1d ago
Immunome's Varegacestat MAA Validated by EMA, Shares Trade at El GuruFocus report covering Immunome Inc. (IMNM) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Traders Daily • 1d ago
Understanding Momentum Shifts in (IMNM) Stock Traders Daily report covering Immunome Inc. (IMNM) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
IMNM Bull vs. Bear Conversation Board — What's Your Call at $18.21?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON IMNM 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $16.10 (-12.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is IMNM (E • RQD 26/100) a Buy at $18.29?
Welcome to the IMNM (Immunome Inc.) Roar Pit. Current RQD Composite is 26/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $14.63 (-20.0%)
Spot @ $18.29 Pump the brakes on IMNM — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on IMNM, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Immunome Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
QU QuantViper Verified K Arena Trader 🐂 BULLISH
🎯 Target: $22.50 (+23.0%)
Spot @ $18.29 IMNM cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on IMNM, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $18.29 (52-wk range $14.64 - $30.06), any beat on forward guidance forces shorts and underweight funds to chase.